Erica Koenig, PhD

Vice President Clinical Development
AbbVie, at the time of the study

Poster(s):

• (87) Efficacy and safety of tavapadon, an orally administered, once-daily, selective D1/D5 dopamine agonist, adjunctive to levodopa for treatment of Parkinson’s disease with motor fluctuations
  Wednesday, October 29, 2025